Aminoglycoside-induced cochleotoxicity

A review

Meiyan Jiang, Takatoshi Karasawa, Peter Steyger

Research output: Contribution to journalReview article

40 Citations (Scopus)

Abstract

Aminoglycoside antibiotics are used as prophylaxis, or urgent treatment, for many life-threatening bacterial infections, including tuberculosis, sepsis, respiratory infections in cystic fibrosis, complex urinary tract infections and endocarditis. Although aminoglycosides are clinically-essential antibiotics, the mechanisms underlying their selective toxicity to the kidney and inner ear continue to be unraveled despite more than 70 years of investigation. The following mechanisms each contribute to aminoglycoside induced toxicity after systemic administration: (1) drug trafficking across endothelial and epithelial barrier layers; (2) sensory cell uptake of these drugs; and (3) disruption of intracellular physiological pathways. Specific factors can increase the risk of drug-induced toxicity, including sustained exposure to higher levels of ambient sound, and selected therapeutic agents such as loop diuretics and glycopeptides. Serious bacterial infections (requiring life-saving aminoglycoside treatment) induce systemic inflammatory responses that also potentiate the degree of ototoxicity and permanent hearing loss.We discuss prospective clinical strategies to protect auditory and vestibular function from aminoglycoside ototoxicity, including reduced cochlear or sensory cell uptake of aminoglycosides, and otoprotection by ameliorating intracellular cytotoxicity.

Original languageEnglish (US)
Article number308
JournalFrontiers in Cellular Neuroscience
Volume11
DOIs
StatePublished - Oct 9 2017

Fingerprint

Aminoglycosides
Bacterial Infections
Drug Trafficking
Anti-Bacterial Agents
Sodium Potassium Chloride Symporter Inhibitors
Glycopeptides
Cochlea
Inner Ear
Endocarditis
Drug-Related Side Effects and Adverse Reactions
Hearing Loss
Cystic Fibrosis
Urinary Tract Infections
Respiratory Tract Infections
Sepsis
Tuberculosis
Kidney
Pharmaceutical Preparations

Keywords

  • Aminoglycosides
  • Cochleotoxicity
  • Gentamicin
  • Inflammation
  • Nephrotoxicity
  • Ototoxicity
  • Systemic administration

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

Aminoglycoside-induced cochleotoxicity : A review. / Jiang, Meiyan; Karasawa, Takatoshi; Steyger, Peter.

In: Frontiers in Cellular Neuroscience, Vol. 11, 308, 09.10.2017.

Research output: Contribution to journalReview article

@article{49d4b0254042438a966ec34428168fed,
title = "Aminoglycoside-induced cochleotoxicity: A review",
abstract = "Aminoglycoside antibiotics are used as prophylaxis, or urgent treatment, for many life-threatening bacterial infections, including tuberculosis, sepsis, respiratory infections in cystic fibrosis, complex urinary tract infections and endocarditis. Although aminoglycosides are clinically-essential antibiotics, the mechanisms underlying their selective toxicity to the kidney and inner ear continue to be unraveled despite more than 70 years of investigation. The following mechanisms each contribute to aminoglycoside induced toxicity after systemic administration: (1) drug trafficking across endothelial and epithelial barrier layers; (2) sensory cell uptake of these drugs; and (3) disruption of intracellular physiological pathways. Specific factors can increase the risk of drug-induced toxicity, including sustained exposure to higher levels of ambient sound, and selected therapeutic agents such as loop diuretics and glycopeptides. Serious bacterial infections (requiring life-saving aminoglycoside treatment) induce systemic inflammatory responses that also potentiate the degree of ototoxicity and permanent hearing loss.We discuss prospective clinical strategies to protect auditory and vestibular function from aminoglycoside ototoxicity, including reduced cochlear or sensory cell uptake of aminoglycosides, and otoprotection by ameliorating intracellular cytotoxicity.",
keywords = "Aminoglycosides, Cochleotoxicity, Gentamicin, Inflammation, Nephrotoxicity, Ototoxicity, Systemic administration",
author = "Meiyan Jiang and Takatoshi Karasawa and Peter Steyger",
year = "2017",
month = "10",
day = "9",
doi = "10.3389/fncel.2017.00308",
language = "English (US)",
volume = "11",
journal = "Frontiers in Cellular Neuroscience",
issn = "1662-5102",
publisher = "Frontiers Research Foundation",

}

TY - JOUR

T1 - Aminoglycoside-induced cochleotoxicity

T2 - A review

AU - Jiang, Meiyan

AU - Karasawa, Takatoshi

AU - Steyger, Peter

PY - 2017/10/9

Y1 - 2017/10/9

N2 - Aminoglycoside antibiotics are used as prophylaxis, or urgent treatment, for many life-threatening bacterial infections, including tuberculosis, sepsis, respiratory infections in cystic fibrosis, complex urinary tract infections and endocarditis. Although aminoglycosides are clinically-essential antibiotics, the mechanisms underlying their selective toxicity to the kidney and inner ear continue to be unraveled despite more than 70 years of investigation. The following mechanisms each contribute to aminoglycoside induced toxicity after systemic administration: (1) drug trafficking across endothelial and epithelial barrier layers; (2) sensory cell uptake of these drugs; and (3) disruption of intracellular physiological pathways. Specific factors can increase the risk of drug-induced toxicity, including sustained exposure to higher levels of ambient sound, and selected therapeutic agents such as loop diuretics and glycopeptides. Serious bacterial infections (requiring life-saving aminoglycoside treatment) induce systemic inflammatory responses that also potentiate the degree of ototoxicity and permanent hearing loss.We discuss prospective clinical strategies to protect auditory and vestibular function from aminoglycoside ototoxicity, including reduced cochlear or sensory cell uptake of aminoglycosides, and otoprotection by ameliorating intracellular cytotoxicity.

AB - Aminoglycoside antibiotics are used as prophylaxis, or urgent treatment, for many life-threatening bacterial infections, including tuberculosis, sepsis, respiratory infections in cystic fibrosis, complex urinary tract infections and endocarditis. Although aminoglycosides are clinically-essential antibiotics, the mechanisms underlying their selective toxicity to the kidney and inner ear continue to be unraveled despite more than 70 years of investigation. The following mechanisms each contribute to aminoglycoside induced toxicity after systemic administration: (1) drug trafficking across endothelial and epithelial barrier layers; (2) sensory cell uptake of these drugs; and (3) disruption of intracellular physiological pathways. Specific factors can increase the risk of drug-induced toxicity, including sustained exposure to higher levels of ambient sound, and selected therapeutic agents such as loop diuretics and glycopeptides. Serious bacterial infections (requiring life-saving aminoglycoside treatment) induce systemic inflammatory responses that also potentiate the degree of ototoxicity and permanent hearing loss.We discuss prospective clinical strategies to protect auditory and vestibular function from aminoglycoside ototoxicity, including reduced cochlear or sensory cell uptake of aminoglycosides, and otoprotection by ameliorating intracellular cytotoxicity.

KW - Aminoglycosides

KW - Cochleotoxicity

KW - Gentamicin

KW - Inflammation

KW - Nephrotoxicity

KW - Ototoxicity

KW - Systemic administration

UR - http://www.scopus.com/inward/record.url?scp=85032003199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032003199&partnerID=8YFLogxK

U2 - 10.3389/fncel.2017.00308

DO - 10.3389/fncel.2017.00308

M3 - Review article

VL - 11

JO - Frontiers in Cellular Neuroscience

JF - Frontiers in Cellular Neuroscience

SN - 1662-5102

M1 - 308

ER -